Leukemia ba'an ee Lymphoblastic (T-ALL) -08

Yesheng oo ka socday Fujian ayaa yidhi, "Haddii aan ka ogaan lahaa CAR-T Ludaopei, mar hore ayaan iman lahaa."

Bishii Sebtembar 2017, Yesheng waxa soo baxay finan wajiga ah, kuwaas oo si tartiib tartiib ah u faafay oo ku biiray balastar. Febraayo 28, 2018, baaritaanka dhuuxa lafta ayaa xaqiijiyay "T-cell lymphoblastic leukemia ba'an" ka dib koorasyo ​​badan oo kiimoterabi ah, oo leh baaritaanno taban oo isdaba joog ah. Dhammaan daawooyinka waa la joojiyay Juun 2019.

Bishii Maajo 2021, Yesheng wuxuu soo bandhigay tiro badan oo ka jira gobolka afka-pharyngeal iyo qanjidhada qoorta oo weyn. Dib-u-eegistii dhuuxa lafta ayaa xaqiijisay soo noqoshada dhammaystiran ee leukemia. Maajo 28, Yesheng waxaa loo wareejiyay Waaxda Labaad ee Hematology ee Isbitaalka Ludaopei si loo dhigo. Baadhitaano dhamaystiran ka dib, ogaanshaha waxa dib loo eegay " leukemia ba'an (T/myeloid biphenotypic)."

Hal wareeg oo kiimoterabi ah ma keenin in dhuuxa lafta laga saaro. Bishii Luulyo 27, Yesheng wuxuu helay faleebo unug CD7 CAR-T ah, oo ay ku xigto daawaynta kiimoterabiga oo ay weheliso daawaynta unugga ee CD7 CAR-T oo iskeed ah. Shan iyo toban maalmood ka dib faleebo, baaritaanka dhuuxa lafta ayaa muujiyay cudur haraa ah oo taban, oo leh fasalka 1aad ee cytokine release syndrome (CRS) oo aan lahayn habdhiska dhexe ee dareenka falcelin xun.